Development and Structural Characterization of UTE‐156, a Covalent Inhibitor of the VCP/p97 AAA+ ATPase
Advanced Science · 2026-05 · 13 (25)
DOI: 10.1002/advs.202520545 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 07.03.2026. Verfasst von Daniela Tamayo-Jaramillo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Valosin Containing Protein, Adenosine Triphosphatases, Enzyme Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
The AAA+ ATPase valosin‐containing protein (VCP/p97) is a central regulator of protein homeostasis that is well characterized for its role in extracting and remodeling ubiquitinated substrates. Dysregulation of VCP activity contributes to the pathogenesis of neurodegenerative diseases and cancer, making it an important therapeutic target. Here, we report the development and characterization of UTE‐156, a novel covalent small‐molecule inhibitor that modifies Cys522 within the D2 ATPase domain of VCP. UTE‐156 potently inhibits VCP ATPase activity, while losing activity against a C522A mutant, supporting a covalent mechanism of action. High‐resolution cryo‐electron microscopy (cryo‐EM) structures reveal that UTE‐156 occupies the D2 nucleotide‐binding site, sterically blocking ATP binding and inducing conformational remodeling of the pocket. Biochemical and cell‐based assays demonstrate strong inhibitory potency but limited solubility and rapid metabolic turnover. These pharmacochemical limitations preclude immediate therapeutic use but underscore its value as a chemical probe. Together, these findings establish UTE‐156 as a powerful tool for dissecting VCP function and provide a framework for future optimization of covalent modulators of protein homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, University of Utah, Salt Lake City, Utah, USA.
- University of Utah Therapeutics Accelerator Hub, University of Utah, Salt Lake City, Utah, USA.
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
- Department of Orthopaedics, University of Utah, Salt Lake City, Utah, USA.
ORCID-Profile: Peter S Shen
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Tamayo-Jaramillo, D., Hegde, S., Jia, X., Coffman, K., Vankayalapati, H., Bearss, D., Jones, K. B., Stark, A. W., & Shen, P. S. (2026). Development and Structural Characterization of UTE‐156, a Covalent Inhibitor of the VCP/p97 AAA+ ATPase. Advanced Science, 13(25). https://doi.org/10.1002/advs.202520545
Vancouver
Tamayo-Jaramillo D, Hegde S, Jia X, Coffman K, Vankayalapati H, Bearss D, et al. Development and Structural Characterization of UTE‐156, a Covalent Inhibitor of the VCP/p97 AAA+ ATPase. Advanced Science. 2026;13(25). doi:10.1002/advs.202520545
BibTeX
@article{TamayoJaramillo2026,
author = {Tamayo-Jaramillo, Daniela and Hegde, Subramanya and Jia, Xuan and Coffman, Kimberly and Vankayalapati, Hariprasad and Bearss, David and Jones, Kevin B and Stark, Alex W and Shen, Peter S},
title = {Development and Structural Characterization of UTE‐156, a Covalent Inhibitor of the VCP/p97 AAA+ ATPase},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {25},
doi = {10.1002/advs.202520545}
}
EUVIMED